Stout has advised ClinTrial Research (“CTR” or the “Company”) on its growth equity round led by Tarsadia Investments. Stout served as exclusive financial advisor to CTR in connection with the transaction, which closed in December 2025.

Founded in 2014 by industry veterans Sam Searcy, Jennifer Yevoli, and Dr. Subhash Gumber, CTR’s growing research site network supports sponsors by furthering research in novel therapies and treatments across multiple therapeutic categories, including behavioral health, neurology, psychiatric, gastrointestinal, nephrology, ophthalmology, respiratory, and pulmonology.

“This investment from Tarsadia is a powerful vote of confidence from a respected industry leader with significant financial and strategic resources. It reinforces CTR's position as a category-defining business,” added Sam Searcy, Founder and Chief Executive Officer of CTR. “From our first meeting with the Tarsadia team last summer, the cultural alignment was immediate. It felt like speaking with close colleagues — effortless, natural, and an extension of our own team. Their intellectual depth and strategic insight are exceptional.”

Tarsadia Investments is a multibillion-dollar private investment management vehicle that makes high-conviction investments in category-defining companies globally. Tarsadia is a supportive and value-enhancing investment partner and has a history of seeking out and working with exceptional management teams. Tarsadia has invested across stages from idea to public ownership, with often a decade-plus investment horizon, using its domain expertise in financial services, healthcare, real estate, and technology to support founders on growth, talent, and M&A/capital raising.